References
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108 https://doi.org/10.3322/caac.21262
- Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16, 1310-1317 https://doi.org/10.1200/JCO.1998.16.4.1310
- Yoshizaki T, Kondo S, Murono S et al (2015) Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma. Jpn J Clin Oncol 45, 244-247 https://doi.org/10.1093/jjco/hyu212
- Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61, 1107-1116 https://doi.org/10.1016/j.ijrobp.2004.07.702
- Lee AW, Poon YF, Foo W et al (1992) Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23, 261-270 https://doi.org/10.1016/0360-3016(92)90740-9
- Galluzzi L, Senovilla L, Vitale I et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 https://doi.org/10.1038/onc.2011.384
- Goldstein M and Kastan MB (2015) The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med 66, 129-143 https://doi.org/10.1146/annurev-med-081313-121208
- Paull TT and Lee JH (2005) The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 4, 737-740 https://doi.org/10.4161/cc.4.6.1715
- Frappart PO, Tong WM, Demuth I et al (2005) An essential function for NBS1 in the prevention of ataxia and cerebellar defects. Nat Med 11, 538-544 https://doi.org/10.1038/nm1228
- So S, Davis AJ and Chen DJ (2009) Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J Cell Biol 187, 977-990 https://doi.org/10.1083/jcb.200906064
- Lamarche BJ, Orazio NI and Weitzman MD (2010) The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 584, 3682-3695 https://doi.org/10.1016/j.febslet.2010.07.029
- Laoukili J, Stahl M and Medema RH (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775, 92-102
- Koo CY, Muir KW and Lam EW (2012) FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 1819, 28-37 https://doi.org/10.1016/j.bbagrm.2011.09.004
- Zhou J, Wang Y, Wang Y et al (2014) FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One 9, e96989 https://doi.org/10.1371/journal.pone.0096989
- Park YY, Jung SY, Jennings NB et al (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33, 1843-1853 https://doi.org/10.1093/carcin/bgs167
- Chua MLK, Wee JTS, Hui EP and Chan ATC (2016) Nasopharyngeal carcinoma. Lancet 387, 1012-1024 https://doi.org/10.1016/S0140-6736(15)00055-0
- Kuo LJ and Yang LX (2008) Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 22, 305-309
- Wang KMsd, Chen ZMsd, Long LMsd et al (2018) iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma. Cancer Biol Ther 19, 1-16 https://doi.org/10.1080/15384047.2017.1394554
- Bensouda Y, Kaikani W, Ahbeddou N et al (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128, 79-85 https://doi.org/10.1016/j.anorl.2010.10.003
- Yu C, Chen L, Yie L et al (2015) Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelialto-mesenchymal transition pathway. Oncol Rep 33, 2402-2410 https://doi.org/10.3892/or.2015.3834
- Jiang L, Wang P and Chen H (2014) Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma. Ups J Med Sci 119, 324-332 https://doi.org/10.3109/03009734.2014.960053
- San Filippo J, Sung P and Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77, 229-257 https://doi.org/10.1146/annurev.biochem.77.061306.125255
- Tauchi H, Kobayashi J, Morishima K et al (2002) Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature 420, 93-98 https://doi.org/10.1038/nature01125
- Nestal de Moraes G, Bella L, Zona S, Burton MJ and Lam EW (2016) Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr Drug Targets 17, 164-177 https://doi.org/10.2174/1389450115666141122211549
- Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB and Menck CFM (2018) DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 73, e478s https://doi.org/10.6061/clinics/2018/e478s
- Salehan MR and Morse HR (2013) DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 70, 31-40 https://doi.org/10.1080/09674845.2013.11669927
- Jiang L, Wang P, Chen L and Chen H (2014) Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol 7, 5450-5460
- Zheng J, Zhang C, Jiang L et al (2011) Functional NBS1 polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma. Mol Carcinog 50, 689-696 https://doi.org/10.1002/mc.20803
- Jiang L, Wu X, Wang P et al (2015) Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol 141, 971-981 https://doi.org/10.1007/s00432-014-1872-3
- Ziebarth AJ, Nowsheen S, Steg AD et al (2013) Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 19, 170-182 https://doi.org/10.1158/1078-0432.CCR-12-1045